GLSI Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 4.17%, SMA50 18.48%, SMA200 107.18%). The stock’s 14-day RSI is 55.89 (neutral), while the ATR of 3.01 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -17.54% below its high and over 261.44% above its low. Average 10-day trading volume of 125.82 thousand shares is below the 3-month average of 153.42 thousand, indicating normal recent market interest.

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) closed at $27.87 USD, gaining $0.68 (2.50%) from the previous close of $27.19. The stock is currently mid-range between its 52-week high and low $7.78 and $34.10. With a market capitalization of about $386.13 million, Greenwich LifeSciences, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.39). Key stats such as the average daily volume over the past year has been around 153.59 thousand shares, volume is running light vs its 52-week average. Headquartered in Stafford, TX, Greenwich LifeSciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Snehal S. Patel, the company employs approximately 4 people and listed since September 25, 2020. Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers.

Greenwich LifeSciences, Inc. generated EPS of -$1.46 over the past year. Five-year average earnings growth is -32.98%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $50.00 to $50.00. The high target offers 83.89% upside. The low target suggests 83.89% downside. The mean target is $50.00. This offers 83.89% upside. Greenwich LifeSciences, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 14, 2025, missed forecasts by 0.0%. The prior quarter beat by 25.0%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in August 14, 2024.

Greenwich LifeSciences, Inc. has 13.63 million shares outstanding. The public float is 6.37 million shares, elevated short interest at 16.30% of float. This equals 1.04 million shares. The short ratio is 13.79 days. Institutional investors hold 21.45% of the float. Insiders own 51.3%. Patel Snehal holds 5.60 million shares, McWilliams David has 620.30 thousand shares and Hallock Kenneth has 397.30 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) shares are flat 1.33% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Greenwich LifeSciences, Inc. trading at a premium to the broader market with a P/E of -19.15. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $48.40, suggesting 78.01% upside. Our AI forecast model points to short-term strength (0.18% over two weeks), a medium-term rise (52.23% over three months), and a longer-term gain (11.81% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Greenwich LifeSciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.18%, with price expected at $27.24 by June 03, 2026, within a range of $25.23 to $29.38 3-Month Outlook: Projected rise of 52.23%, reaching $41.39 by August 19, 2026, with a range of $40.88 to $41.85. 1-Year Outlook: Projected gain of 11.81%, with price at $30.40 by May 21, 2027, within a range of $28.58 to $31.96.

Greenwich LifeSciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.31. This means the shares are trading above this model’s fair value.

Greenwich LifeSciences, Inc. trades at a P/E ratio of -19.15, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 170.69 reflecting a rich premium to book value. The P/FCF stands at -44.09, also below market averages. Compared to sector medians, Greenwich LifeSciences, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.